Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 3/20 | 0.72 |
| ▸ | DRD2 | P14416 | 3/20 | 0.53 |
| ▸ | DRD3 | P35462 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31172405 | 1.00 | ADRA2C (0.72) | ADRA2CDRD2DRD3MAPTKDM4E | |
| SCHEMBL23124021 | 0.93 | ADRA2C (0.64) | ADRA2CDRD2DRD3MAPTKDM4E | |
| SCHEMBL29586390 | 0.84 | ADRA2C (1.00) | ADRA2CDRD2DRD3MAPTKDM4E | |
| SCHEMBL1926749 | 0.84 | ADRA2C (1.00) | ADRA2CDRD2DRD3MAPTKDM4E | |
| SCHEMBL3555024 | 0.83 | ADRA2C (0.59) | ADRA2CDRD2DRD3MAPTKDM4E | |
| SCHEMBL23122995 | 0.82 | ADRA2C (0.50) | ADRA2CDRD2DRD3MAPTKDM4E | |
| SCHEMBL23122730 | 0.82 | KEAP1 (0.61) | ADRA2CMAPTKDM4EMAPK1GAA | |
| SCHEMBL31172356 | 0.82 | KEAP1 (0.67) | ADRA2CMAPTKDM4EMAPK1GAA | |
| SCHEMBL23294841 | 0.81 | ADRA2C (0.58) | ADRA2CDRD2DRD3MAPTKDM4E | |
| SCHEMBL1127096 | 0.81 | ADRA2C (0.68) | ADRA2CDRD2DRD3MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3755688-B1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS | ADAMED PHARMA S A (PL) | 2023-06-14 | — | — | EP | disclosed |
| US-20220380319-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-01 | — | — | US | disclosed |
| EP-4031532-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Bial-R&D Investments, S.A. (PT) | 2022-07-27 | — | — | EP | disclosed |
| CN-114787136-A | Substituted benzimidazole carboxamides and their use in the treatment of medical disorders | 比亚尔R&D投资股份公司 | 2022-07-22 | — | — | CN | disclosed |
| US-11332470-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20210363139-A1 | CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS, INC. | 2021-11-25 | — | — | US | disclosed |
| US-10988465-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| WO-2021055591-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL-BioTech Investments, Inc. (US) | 2021-03-25 | — | — | WO | disclosed |
| US-20200255414-A1 | CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS, INC. | 2020-08-13 | — | — | US | disclosed |
| US-20200155525-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC | 2020-05-21 | — | — | US | disclosed |
| CN-1495171-A | Indazol compound for inhibiting protein kinase and medicine composition and their application | ������ҩ������˾ | 2004-05-12 | — | — | CN | disclosed |
| CN-1137884-C | Indazole compounds and pharmaceutical compositions that inhibit protein kinases and methods of use thereof | ������ҩ������˾ | 2004-02-11 | — | — | CN | disclosed |
| US-6534524-B1 | Antiproliferative agents, including axitinib | AGOURON PHARMACEUTICALS, INC. | 2003-03-18 | — | — | US | disclosed |
| US-6531491-B1 | Methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, | AGOURON PHARAMACEUTICALS, INC. | 2003-03-11 | — | — | US | disclosed |
| CN-1374950-A | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases and their use | AGOURON PHARMACETUICALS INC (US) | 2002-10-16 | — | — | CN | disclosed |
| EP-1218348-A2 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001002369-A2 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2001-01-11 | — | — | WO | disclosed |
| US-6051570-A | ANTIULCER AGENTS | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-04-18 | — | — | US | disclosed |
| EP-0983263-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS ANTIULCER AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998054172-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS ANTIULCER AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255414-A1 | CXCR4 INHIBITORS AND USES THEREOF | CXCR4, CXCL12, CXCR3 | ADRA2C 1193/4885DRD2 3395/4885DRD3 2827/4885 |
| US-20210363139-A1 | CXCR4 INHIBITORS AND USES THEREOF | CXCR4, CXCL12, CXCR3 | ADRA2C 1193/4885DRD2 3395/4885DRD3 2827/4885 |
| US-10988465-B2 | CXCR4 inhibitors and uses thereof | CXCR4, CXCL12, CXCR3 | ADRA2C 1193/4885DRD2 3395/4885DRD3 2827/4885 |
| US-20220380319-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GAA, GBA1, CLN6 | ADRA2C 3389/4885DRD2 4257/4885DRD3 4520/4885 |
| US-11332470-B2 | CXCR4 inhibitors and uses thereof | CXCR4, CXCL12, CXCR3 | ADRA2C 1193/4885DRD2 3395/4885DRD3 2827/4885 |
| US-20200155525-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | COL1A1, NOX4, FGF1 | ADRA2C 1395/4885DRD2 4829/4885DRD3 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.